DCM
CRSP icon

Deuterium Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Deuterium Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.36M Hold
25,000
– – 1.48% 14
2026
Q1 		$1.19M Buy
+25,000
New +$1.32M 1.38% 16
2022
Q2 		– Sell
-18,000
Closed -$1.13M – 60
2022
Q1 		$1.13M Hold
18,000
– – 1.45% 13
2021
Q4 		$1.36M Buy
+18,000
New +$1.57M 2.02% 10

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Deuterium Capital Management's CRSP Position: Q2 2026 in Review

Deuterium Capital Management held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 25,000 shares worth $1.36M. The position accounts for 1.48% of the portfolio, ranked #14.

Deuterium Capital Management first reported a position in CRSP in Q4 2021 and has held it in 4 quarters since. The position peaked at $1.36M in Q4 2021. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Deuterium Capital Management held 25,000 shares of CRISPR Therapeutics worth $1.36M as of Q2 2026.
  • Deuterium Capital Management left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up 1.48% of Deuterium Capital Management's portfolio in Q2 2026, its #14 holding.
  • Deuterium Capital Management first reported a position in CRISPR Therapeutics in Q4 2021 and has held it in 4 quarters since.
  • Deuterium Capital Management's CRISPR Therapeutics position peaked at $1.36M in Q4 2021.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Deuterium Capital Management's 13F filing for Q2 2026, filed 5 Aug 2026.